SG Americas Securities’s FibroBiologics FBLG Stock Holding History

SG Americas Securities’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,026	Closed	-$18K	–	3693
2025 Q1	$18K	Buy	+1,026	New	+$29.3K	﹤0.01%	3387

Other funds holding FBLG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

YAG

Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CFP

Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SG Americas Securities's FBLG Position: Q2 2025 in Review

SG Americas Securities sold out of FibroBiologics (FBLG) in Q2 2025, closing a stake of 1,026 shares — an estimated $18K sold.

SG Americas Securities first reported a position in FBLG in Q1 2025 and held it in 1 quarter. The position peaked at $18K in Q1 2025. 57 funds tracked by Wall St. Rank hold FBLG as of Q2 2025.

SG Americas Securities reported no remaining FibroBiologics position as of Q2 2025 after selling out during the quarter.
SG Americas Securities sold 1,026 FibroBiologics shares in Q2 2025, an estimated $18K.
SG Americas Securities first reported a position in FibroBiologics in Q1 2025 and held it in 1 quarter.
SG Americas Securities's FibroBiologics position peaked at $18K in Q1 2025.
57 funds tracked by Wall St. Rank held FibroBiologics as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.